Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

被引：5

作者：

Tan, Antoinette R. ^{[1
]}

Im, Seock-Ah ^{[2
]}

Mattar, Andre ^{[3
]}

Colomer, Ramon ^{[4
]}

Stroyakovskii, Daniil ^{[5
]}

Nowecki, Zbigniew ^{[6
]}

De laurentiis, Michelino ^{[7
]}

Pierga, Jean-Yves ^{[8
]}

Jung, Kyung Hae ^{[9
]}

Schem, Christian ^{[10
]}

Heeson, Sarah ^{[11
]}

Shivhare, Mahesh ^{[12
]}

Kirschbrown, Whitney P. ^{[13
]}

Restuccia, Eleonora ^{[14
]}

Crnjevic, Tanja Badovinac ^{[14
]}

Jackisch, Christian ^{[15
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Hosp Perola Byington, Sao Paulo, SP, Brazil

[4] Hosp Univ La Princesa, Madrid, Spain

[5] City Clin Oncol Hosp 62, Moscow, Russia

[6] Ctr Onkol Inst, Warsaw, Poland

[7] Natl Canc Inst, Naples, Italy

[8] Inst Curie, Oncol Med, Paris, France

[9] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[10] Mammazentrum Hamburg, Hamburg, Germany

[11] Roche Prod Ltd, Welwyn Garden City, Herts, England

[12] F Hoffmann La Roche Ltd, Basel, Switzerland

[13] Genentech Inc, San Francisco, CA 94080 USA

[14] F Hoffmann La Roche & Cie AG, Basel, Switzerland

[15] Sana Klinikum Offenbach GmbH, Offenbach, Germany

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS19-PD4-07

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD4-07

引用

页数：4